FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to the application of desPro36exendin-4(1-39)-Lys6-NH2 or its pharmaceutically acceptable salt for the production of a medication for treatment of type 2 diabetes mellitus and/or stimulation of the body weight reduction in patients with type 2 diabetes, where the said patient with type 2 diabetes, subjected to treatment, has a 2-hour postprandial concentration of glucose in plasma at least 14 mmol/l and does not receive anti-diabetes treatment.
EFFECT: group of inventions is effective in the treatment of type 2 diabetes mellitus and/or stimulation of the body weight reduction in the patients with type 2 diabetes.
15 cl, 6 dwg, 25 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH DIABETES TYPE 2 | 2012 |
|
RU2583134C2 |
| PHARMACEUTICAL COMBINATION FOR USE FOR INDUCING WEIGHT LOSS IN SUBJECTS WITH TYPE 2 DIABETES OR/AND FOR PREVENTING WEIGHT GAIN IN SUBJECTS WITH TYPE 2 DIABETES | 2012 |
|
RU2761624C2 |
| LIXISENATIDE AS ADD-ON THERAPY TO BASAL INSULIN IN TYPE 2 DIABETES | 2012 |
|
RU2606154C2 |
| PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2012 |
|
RU2650616C2 |
| PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2012 |
|
RU2572703C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| TREATMENT OF DIABETES MELLITUS USING LONG-ACTING INSULIN COMPOUNDS | 2014 |
|
RU2834367C2 |
| INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION | 2014 |
|
RU2684398C2 |
| TREATING DIABETES MELLITUS WITH LONG-ACTING INSULIN FORMULATIONS | 2014 |
|
RU2705797C2 |
| USE OF SUPER-HIGH-SPEED INSULIN | 2014 |
|
RU2688663C2 |
